We have updated our privacy policy. If you have any question, contact us at privacy@scicrunch.org. Dismiss and don't show again

Searching across hundreds of databases

Our searching services are busy right now. Your search will reload in five seconds.

Forgot Password

If you have forgotten your password you can enter your email here and get a temporary password sent to your email.

Chronic pharmacological mGlu5 inhibition corrects fragile X in adult mice.

Neuron | Apr 12, 2012

Fragile X syndrome (FXS) is the most common form of inherited intellectual disability. Previous studies have implicated mGlu5 in the pathogenesis of the disease, but a crucial unanswered question is whether pharmacological mGlu5 inhibition is able to reverse an already established FXS phenotype in mammals. Here we have used the novel, potent, and selective mGlu5 inhibitor CTEP to address this issue in the Fmr1 knockout mouse. Acute CTEP treatment corrects elevated hippocampal long-term depression, protein synthesis, and audiogenic seizures. Chronic treatment that inhibits mGlu5 within a receptor occupancy range of 81% ± 4% rescues cognitive deficits, auditory hypersensitivity, aberrant dendritic spine density, overactive ERK and mTOR signaling, and partially corrects macroorchidism. This study shows that a comprehensive phenotype correction in FXS is possible with pharmacological intervention starting in young adulthood, after development of the phenotype. It is of great interest how these findings may translate into ongoing clinical research testing mGlu5 inhibitors in FXS patients.

Pubmed ID: 22500629 RIS Download

Mesh terms: Age Factors | Animals | Disease Models, Animal | Drug Administration Schedule | Excitatory Amino Acid Antagonists | Fragile X Mental Retardation Protein | Fragile X Syndrome | Hippocampus | Imidazoles | Male | Mice | Mice, Knockout | Phenotype | Pyridines | Receptor, Metabotropic Glutamate 5 | Receptors, Metabotropic Glutamate